BCDA vs. SPRO, OSTX, BRNS, ATHE, RAPT, INKT, QTTB, ESLA, ANVS, and TPST
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Spero Therapeutics (SPRO), OS Therapies (OSTX), Barinthus Biotherapeutics (BRNS), Alterity Therapeutics (ATHE), RAPT Therapeutics (RAPT), MiNK Therapeutics (INKT), Q32 Bio (QTTB), Estrella Immunopharma (ESLA), Annovis Bio (ANVS), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.
BioCardia vs.
BioCardia (NASDAQ:BCDA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 982.25%. Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 501.68%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than Spero Therapeutics.
BioCardia has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Spero Therapeutics has a net margin of 3.30% compared to BioCardia's net margin of -1,999.77%. Spero Therapeutics' return on equity of 4.03% beat BioCardia's return on equity.
Spero Therapeutics received 192 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 69.67% of users gave Spero Therapeutics an outperform vote while only 60.71% of users gave BioCardia an outperform vote.
Spero Therapeutics has higher revenue and earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
20.6% of BioCardia shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 4.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, BioCardia's average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score.
Summary
Spero Therapeutics beats BioCardia on 11 of the 17 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
This page (NASDAQ:BCDA) was last updated on 2/22/2025 by MarketBeat.com Staff
